Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 31.08% is 24% above its 5-year average of 25.03%, near the high end of its 5-year range (15.86%–33.79%).
1.76% above its 12-month average of 30.54%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2019 (2019-12-31): 30.18%.
EBITDA MARGIN
31.08%
EBITDA MARGIN AVG TTM
30.54%
EBITDA MARGIN AVG 3Y
27.28%
EBITDA MARGIN AVG 5Y
25.03%
EBITDA MARGIN AVG 10Y
16.30%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.76%
CURRENT VS 3Y AVG
+13.93%
CURRENT VS 5Y AVG
+24.16%
CURRENT VS 10Y AVG
+90.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$32.93M
EBITDA Margin
-108.41%
TTM Avg
-31.49%
3Y Avg
5.24%
5Y Avg
21.14%
Market Cap
$33.29M
EBITDA Margin
-3982.39%
TTM Avg
-3087.93%
3Y Avg
-1849.71%
5Y Avg
-2051.20%
Market Cap
$31.52M
EBITDA Margin
2.14%
TTM Avg
1.67%
3Y Avg
3.35%
5Y Avg
2.87%
Market Cap
$33.61M
EBITDA Margin
-7905.63%
TTM Avg
-7905.63%
3Y Avg
-7905.63%
5Y Avg
-7905.63%
Market Cap
$33.63M
EBITDA Margin
-884.81%
TTM Avg
-512.51%
3Y Avg
-340.78%
5Y Avg
-266.52%
Market Cap
$31.11M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$30.92M
EBITDA Margin
-10097.04%
TTM Avg
-6618.17%
3Y Avg
-8743.58%
5Y Avg
-8072.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HeartBeam, Inc. (BEAT) | $32.42M | 31.08% | 30.54% | 27.28% | 25.03% |
| Nephros, Inc. (NEPH)vs › | $32.79M | 6.84% | 3.92% | -9.89% | -19.41% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | -108.41% | -31.49% | 5.24% | 21.14% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | -3982.39% | -3087.93% | -1849.71% | -2051.20% |
| Nortech Systems Incorporated (NSYS)vs › | $31.52M | 2.14% | 1.67% | 3.35% | 2.87% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
| Scilex Holding Company (SCLX)vs › | $33.63M | -884.81% | -512.51% | -340.78% | -266.52% |
| Accuray Incorporated (ARAY)vs › | $31.11M | -6.58% | -1.77% | -0.14% | 1.64% |
| CervoMed Inc. (CRVO)vs › | $30.92M | -10097.04% | -6618.17% | -8743.58% | -8072.84% |
| MDxHealth S.A. (MDXH)vs › | $30.81M | -5.74% | -12.14% | -35.62% | -63.06% |
Gross Margin
0.0%
EBITDA Margin
31.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2019-12-31 | 30.18% |
| 2019-09-30 | 30.33% |
| 2019-06-30 | 29.98% |
| 2019-03-31 | 29.28% |
| 2018-12-31 | 32.94% |
| 2018-09-30 | 33.79% |
| 2018-06-30 | 30.53% |
| 2018-03-31 | 26.77% |
| 2017-12-31 | 30.61% |
| 2017-09-30 | 18.90% |
| 2017-06-30 | 22.55% |
| 2017-03-31 | 16.84% |
| 2016-12-31 | 21.95% |
| 2016-09-30 | 25.26% |
| 2016-06-30 | 24.35% |
| 2016-03-31 | 24.79% |
| 2015-12-31 | 20.71% |
| 2015-09-30 | 22.52% |
| 2015-06-30 | 20.01% |
| 2015-03-31 | 17.54% |
| 2014-12-31 | 15.86% |
| 2014-09-30 | 15.31% |
| 2014-06-30 | 15.16% |
| 2014-03-31 | 11.39% |
| 2013-12-31 | 17.11% |
| 2013-09-30 | 16.94% |
| 2013-06-30 | 15.59% |
| 2013-03-31 | 14.32% |
| 2012-12-31 | 39.65% |
| 2012-09-30 | -0.65% |
| 2012-06-30 | 4.29% |
| 2012-03-31 | -4.77% |
| 2011-12-31 | 3.80% |
| 2011-09-30 | -10.47% |
| 2011-06-30 | 4.48% |
| 2011-03-31 | 5.34% |
| 2010-12-31 | -3.13% |
| 2010-09-30 | -13.18% |
| 2010-06-30 | 6.15% |
| 2010-03-31 | 13.29% |
| 2009-12-31 | -7.82% |
| 2009-09-30 | -6.50% |
| 2009-06-30 | 12.39% |
| 2009-03-31 | 9.25% |
| 2008-12-31 | 26.37% |
| 2008-09-30 | 21.06% |
| 2008-06-30 | 17.36% |
| 2008-03-31 | 9.88% |
| 2007-12-31 | -91.01% |
| 2006-12-31 | -37.24% |
